Hananja

Hananja is a South Korean biotechnology company dedicated to developing innovative therapies for rare and chronic kidney diseases. The company's primary focus is on Alport syndrome, a genetic condition characterized by progressive kidney damage, for which there are currently limited treatment options. Hananja's lead research program involves small molecule inhibitors targeting the TGF-beta signaling pathway to prevent renal fibrosis and preserve kidney function. By addressing the underlying mechanisms of glomerular basement membrane degradation, the company aims to provide disease-modifying treatments for patients with hereditary and metabolic renal disorders.